{"id":"bcd-085-q4w","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Decreased hemoglobin"}]},"_chembl":{"chemblId":"CHEMBL5917475","moleculeType":null,"molecularWeight":"374.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BCD-085 binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing interaction with PD-1 receptors on T cells. This blockade restores anti-tumor immune responses by releasing the 'brakes' on T cell activation and proliferation. The drug is designed as a quarterly (Q4W) dosing regimen for improved patient convenience.","oneSentence":"BCD-085 is a monoclonal antibody that blocks the PD-L1 checkpoint, enabling the immune system to recognize and attack cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:39.307Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT03390101","phase":"PHASE3","title":"An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Biocad","startDate":"2017-12-26","conditions":"Moderate to Severe Plaque Psoriasis","enrollment":213}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BCD-085"],"phase":"phase_3","status":"active","brandName":"BCD-085 Q4W","genericName":"BCD-085 Q4W","companyName":"Biocad","companyId":"biocad","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BCD-085 Q4W is a treatment being studied in a clinical trial for moderate to severe plaque psoriasis. The study is a randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of two dosing regimens of BCD-085, including Q4W, to a placebo.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}